NewsRamp is a PR & Newswire Technology platform that enhances press release distribution by adapting content to align with how and where audiences consume information. Recognizing that most internet activity occurs outside of search, NewsRamp improves content discovery by programmatically curating press releases into multiple unique formats—news articles, blog posts, persona-based TLDRs, videos, audio, and Zero-Click content—and distributing this content through a network of news sites, blogs, forums, podcasts, video platforms, newsletters, and social media.
FAQ: Lantern Pharma's AI Center of Excellence and Advanced Agentic Labs in India
TL;DR
Lantern Pharma's new AI hub in Bengaluru accelerates drug discovery, giving the company a strategic advantage in oncology and expanding into new disease areas.
The Bengaluru center scales Lantern's RADR AI platform with increased computational power and talent to develop large language models for molecular assessment and drug generation.
This initiative advances precision oncology therapies and expands to other diseases, potentially improving patient outcomes and making treatments more accessible globally.
Lantern Pharma is industrializing AI drug discovery in India, using massive data to create new cancer drugs while maintaining cash-neutral operations.
Found this article helpful?
Share it with your network and spread the knowledge!
Lantern Pharma announced the establishment of an AI Center of Excellence and Advanced Agentic Labs in Bengaluru, India, marking a strategic inflection point as the company moves to industrialize its AI-enabled drug discovery capabilities at global scale.
The AI Center of Excellence and Advanced Agentic Labs is being established in Bengaluru, India.
The Bengaluru hub will serve as Lantern's global scale-up center for its proprietary RADR® AI platform, expanding computational capacity, technical talent, and continuous development cycles to support both its internal oncology pipeline and a growing roster of pharmaceutical and academic collaborators.
Lantern Pharma's proprietary RADR® AI platform integrates hundreds of billions of data points to identify biomarkers, predict drug response, and design smarter clinical trials for oncology drug development.
The initiative will accelerate development of Lantern's specialized large language and quantitative models for molecular assessment, optimization, and de novo drug generation, while enabling phased expansion beyond oncology into additional disease areas.
The expansion will maintain a cash-neutral financial impact during early deployment.
Lantern Pharma is a clinical-stage biotechnology company focused on using artificial intelligence, machine learning, and genomic data to streamline oncology drug development and bring precision therapies to patients.
Lantern's clinical-stage pipeline includes LP-184, LP-284, and LP-300, each targeting genomically defined patient populations.
The latest news and updates relating to LTRN are available in the company's newsroom at https://ibn.fm/LTRN
AINewsWire is a specialized communications platform focused on AI advancements that published this announcement, and it's one of 75+ brands within the Dynamic Brand Portfolio @ IBN that provides various distribution and communication services.
Curated from InvestorBrandNetwork (IBN)
